Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression

Clinical Cancer Research

Volumn 7, Issue 6, 2001, Pages 1773-1781

  Lin, D L ^a   Whitney, M C ^a   Yao, Z ^a   Keller, E T ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; CYTOKINE; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN; WORTMANNIN;

ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GENE ACTIVATION; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE INDUCTION; HORMONE RESPONSE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER;

ANILIDES; BLOTTING, WESTERN; CELL NUCLEUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLAVONOIDS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GAMMARETROVIRUS; HUMANS; IMIDAZOLES; INTERLEUKIN-6; MALE; MICROSCOPY, FLUORESCENCE; MITOGEN-ACTIVATED PROTEIN KINASES; PLASMIDS; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PYRIDINES; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TUMOR CELLS, CULTURED; TYRPHOSTINS; UP-REGULATION;

EID: 0034901655     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation
2. Development of androgen resistance in prostatic cancer
3. Growth factors in human prostate cancer cells: Implications for an improved treatment of prostate cancer
4. Cell-specific toxicity of a chimeric protein composed of interleukin-6 and Pseudomonas exotoxin (IL6-PE40) on tumor cells
5. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro
6. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty
7. Leukemia inhibitory factor and interleukin-6 trigger the same immediate early response, including tyrosine phosphorylation, upon induction of myeloid leukemia differentiation
8. Interleukin-6 signals activatingjunB and TIS11 gene transcription in a B-cell hybridoma
9. The signalling pathways of interleukin-6 and y interferon converge by the activation of different transcription factors which bind to common responsive DNA elements
10. Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia
11. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue
12. The steroid and thyroid hormone receptor superfamily
13. The androgen receptor in prostate cancer
14. Inability of cytoplasmic or nuclear androgen receptor content or distribution to distinguish benign from carcinomatous human prostate
15. LNCaP model of human prostatic carcinoma
16. Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth. EGF-receptor level and acid phosphatase secretion
17. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells. LNCaP, by dihydrotestosterone
18. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor
19. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells
20. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells
21. 1 arrest through induction of p27(Kipl), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells
22. The hormone response element of the mouse mammary tumour virus DNA mediates the progestin and androgen induction of transcription in the proviral long terminal repeat region
23. The linkage of Kennedy's neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator
24. The stringency and magnitude of androgen-specific gene activation are combinatorial functions of receptor and nonreceptor binding site sequences
25. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells
26. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines
27. Interleukin-6 and prostate cancer progression
28. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter
29. Steroidal antiandrogens and 5α-reductase inhibitors
30. Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation
31. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
32. Activation of the human androgen receptor through a protein kinase A signaling pathway
33. Phorbol ester causes ligand-independent activation of the androgen receptor
34. Androgen-independent induction of prostate- specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways
35. Tec tyrosine kinase links the cytokine receptors to PI-3 kinase probably through JAK
36. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells
37. Antiapoptotic signaling in LNCaP prostate cancer cells: A survival signaling pathway independent of phosphatidylinositol 3′-kinase and Akt/protein kinase B
38. Cross-talk between peptide growth factor and estrogen receptor signaling pathways
39. Molecular mechanism of action of a steroid hormone receptor
40. Interleukin-6: A candidate mediator of human prostate cancer morbidity
41. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway
42. Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity
43. Function of Ras as a molecular switch in signal transduction
44. Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy
45. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer
46. Distant metastases from prostatic carcinoma express androgen receptor protein
47. Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: A Phase I assessment
48. Cytokine variations in patients with hormone treated prostate cancer
49. Serum interleukin 6 as a prognostic factor in patients with prostate cancer
50. Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma
51. Relationship between serum levels of interleukin-6, tumor necrosis factor-α and bone turnover markers in prostate cancer patients
52. Characterization of the role of IL-6 in the progression of prostate cancer
53. Bicalutamide in advanced prostate cancer. A review
54. Functional analysis of the human androgen receptor promoter
55. Induction of translation by the 5′-untranslated region of human androgen receptor mRNA
56. Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter
57. Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated upregulation of AR messenger RNA
58. Homologous androgen receptor up-regulation in osteoblastic cells may be associated with enhanced functional androgen responsiveness
59. Distribution and hormonal regulation of androgen receptor (AR) and AR messenger ribonucleic acid in the rat hippocampus
60. Up-regulation of the levels of androgen receptor and its mRNA by androgens in smooth-muscle cells from rat penis
61. Inhibition of NFκB activity through maintenance of IκBα levels contributes to dihydrotes-tosterone-mediated repression of the interleukin-6 promoter
62. Orchiectomy increases bone marrow interleukin-6 levels in mice
63. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor